Seastar Medical Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seastar Medical Holding Corp. (the "Company") on December 27, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Denver, CO. The report details a material definitive agreement entered into on the date of the report.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreements
On December 27, 2022, the Company entered into a License and Distribution Agreement with Nuwellis, Inc. ("Nuwellis"). Key terms include:
- Exclusive Distribution: Nuwellis is appointed as the exclusive distributor for the Company's Selective Cytopheretic Device ("SCD") product in the United States.
- Regulatory Trigger: The agreement becomes effective following FDA authorization to market the SCD product for pediatric use under a Humanitarian Device Exemption application.
- Compensation Structure: The Company will receive an upfront payment, milestone payments upon achieving specific targets, and royalties on gross sales of the SCD product.
- Term: The initial term commences on December 27, 2022, and ends on the three-year anniversary of the earlier of (a) 90 days after FDA authorization or (b) the first commercial sale. The term may be automatically extended for two additional one-year periods.
- Termination: Either party may terminate for material breach if not cured within 90 days of written notice. The Company retains additional termination rights.
Outlook, Risks, and Management Commentary
Management announced the agreement via a joint press release with Nuwellis on December 29, 2022. The agreement is contingent upon receiving FDA authorization for pediatric use. The full text of the agreement is expected to be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2022. No specific risks or contingencies beyond the regulatory approval requirement and standard breach provisions are detailed in this filing.
Investor Verification Checklist
- Verify the status of the FDA Humanitarian Device Exemption application for pediatric use of the SCD product.
- Review the full text of the Distribution Agreement (to be filed in the 2022 Form 10-K) for specific details on the upfront payment amount, milestone definitions, and royalty rates.
- Confirm Nuwellis, Inc.'s distribution capabilities and market reach for pediatric medical devices.
- Monitor for any updates regarding the timing of the first commercial sale of the SCD product.